Lifecore Biomedical Inc. (LFCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lifecore Biomedical Inc. (LFCR) has a cash flow conversion efficiency ratio of 0.226x as of February 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.70 Million) by net assets ($20.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LFCR days of operational coverage to measure how many days the company can operate on defensive assets alone.
Lifecore Biomedical Inc. - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Lifecore Biomedical Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lifecore Biomedical Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lifecore Biomedical Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SICHUAN ENG.INV.DEV.H YC1
F:84H
|
N/A |
|
Bicycle Therapeutics Ltd
NASDAQ:BCYC
|
-0.115x |
|
Polytronics Technology Corp
TW:6224
|
0.010x |
|
Zhonglu Co Ltd A
SHG:600818
|
-0.026x |
|
RCI Hospitality Holdings Inc
NASDAQ:RICK
|
0.051x |
|
Acrow Ltd
AU:ACF
|
0.085x |
|
Onward Medical N.V.
BR:ONWD
|
-0.366x |
|
GENFIT S.A. ADR/1 EO-25
F:XUPB
|
N/A |
Annual Cash Flow Conversion Efficiency for Lifecore Biomedical Inc. (1996–2025)
The table below shows the annual cash flow conversion efficiency of Lifecore Biomedical Inc. from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see LFCR stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-05-31 | $1.34 Million | $-206.00K | -0.154x | -778.86% |
| 2024-05-31 | $11.31 Million | $257.00K | 0.023x | +108.83% |
| 2023-05-31 | $87.82 Million | $-22.59 Million | -0.257x | -13.81% |
| 2022-05-31 | $107.94 Million | $-24.40 Million | -0.226x | -378.28% |
| 2021-05-31 | $202.78 Million | $16.47 Million | 0.081x | +210.12% |
| 2020-05-31 | $231.04 Million | $-17.04 Million | -0.074x | -224.38% |
| 2019-05-31 | $270.14 Million | $16.02 Million | 0.059x | -24.28% |
| 2018-05-31 | $252.56 Million | $19.78 Million | 0.078x | -39.08% |
| 2017-05-31 | $228.15 Million | $29.33 Million | 0.129x | +25.30% |
| 2016-05-31 | $212.35 Million | $21.78 Million | 0.103x | -13.67% |
| 2015-05-31 | $220.11 Million | $26.16 Million | 0.119x | +15.62% |
| 2014-05-31 | $204.76 Million | $21.05 Million | 0.103x | -12.66% |
| 2013-05-31 | $180.41 Million | $21.23 Million | 0.118x | -19.60% |
| 2012-05-31 | $151.56 Million | $22.18 Million | 0.146x | +39.31% |
| 2011-05-31 | $137.73 Million | $14.47 Million | 0.105x | +85.99% |
| 2010-05-31 | $132.47 Million | $7.48 Million | 0.056x | -23.85% |
| 2009-05-31 | $127.20 Million | $9.44 Million | 0.074x | -50.88% |
| 2008-05-31 | $116.02 Million | $17.52 Million | 0.151x | +920.78% |
| 2007-05-31 | $112.07 Million | $-2.06 Million | -0.018x | -114.70% |
| 2006-05-31 | $86.82 Million | $10.87 Million | 0.125x | -29.48% |
| 2005-05-31 | $73.53 Million | $13.05 Million | 0.177x | +41.16% |
| 2004-05-31 | $63.10 Million | $7.93 Million | 0.126x | +7262.63% |
| 2002-05-31 | $57.54 Million | $-101.00K | -0.002x | +98.82% |
| 2001-05-31 | $50.87 Million | $-7.57 Million | -0.149x | -269.33% |
| 2000-05-31 | $57.00 Million | $5.01 Million | 0.088x | +177.61% |
| 1999-05-31 | $31.80 Million | $-3.60 Million | -0.113x | -12.21% |
| 1998-05-31 | $33.70 Million | $-3.40 Million | -0.101x | +34.70% |
| 1997-05-31 | $35.60 Million | $-5.50 Million | -0.154x | -57.07% |
| 1996-05-31 | $36.60 Million | $-3.60 Million | -0.098x | -- |
About Lifecore Biomedical Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device … Read more